Dr. Manu Chakravarthy is a physician–scientist internationally recognized as a thought leader in metabolic diseases and drug development. He currently serves as Global Head of Cardiovascular, Renal, and Metabolism Product Development at Roche-Genentech. Previously, he was the Head of R&D and Chief Scientific & Medical Officer at Carmot Therapeutics, playing a pivotal role in its 2024 acquisition by Roche. His experience also includes executive leadership positions at Axcella Therapeutics, Eli Lilly, and as a Distinguished Scientist at Merck. He earned his M.D. and Ph.D. from the Univ of Texas and MD Anderson Cancer Center, completed clinical and subspeciality training in Internal Medicine and Endocrinology at the Univ of Pennsylvania and Washington University in St. Louis.